Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Reaches New 1-Year High – Here’s What Happened

Posted by Samantha Reynolds on Oct 22nd, 2024

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF – Get Free Report)’s share price reached a new 52-week high during trading on Monday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares traded. The stock had previously closed at $52.25.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Check Out Our Latest Stock Analysis on RCDTF

Recordati Industria Chimica e Farmaceutica Stock Performance

The firm has a market cap of $10.78 billion, a PE ratio of 26.13 and a beta of 0.33. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The stock’s 50 day moving average price is $52.25 and its 200 day moving average price is $51.86.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. The business had revenue of $622.00 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%.

Recordati Industria Chimica e Farmaceutica Company Profile

(Get Free Report)

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.